Andros Pharmaceuticals Co.,Ltd

NT$29.65As of Sun 8 Nov 2026, 12:00 UTC

TPEx:6917Healthcare

Country Taiwan

PE (Fwd) —

TSR 4Y CAGR (6.82%)

Div yield —

ROE (11.82%)

Biotechnology

Beta (5Y) —

PE TTM —

TSR TTM 47.15%

Mkt cap NT$1.817B

ROIC (17.67%)

SE Grade™

—

Value

Quality

Moat

1Y Price

Reference

NT$31

3.18%

(95.18%)

Price above Reference Value

TTM

FYE 31 Dec TWD

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

5.548

RevenueNT$M

—

1.713

0.805

0.203

5.548

6.689

47.95%

—

2633.00

Revenue growth%

—

(53.01)

(74.78)

2633.00

20.56

(53.01)

—

32.44

Gross margin%

—

56.39

38.88

4.93

32.44

31.35

35.66

—

(1363.30)

Operating margin%

—

(2729.77)

(9156.52)

(44142.86)

(1363.30)

(100.00)

(5943.15)

—

(969.29)

Net margin%

—

(2403.74)

(8466.96)

(38561.08)

(969.29)

(100.00)

(5435.35)

—

P/E ratio (avg)x

—

EV/EBITx

—

(3.38)

FCF yield (avg)%

—

(3.79)

(9.46)

(4.58)

(0.49)

(4.58)

—

(836.97)

FCF margin%

—

(2090.19)

(5866.09)

(41096.06)

(836.97)

(100.00)

(3978.14)

—

0.863

FCF / Net incomex

—

0.870

0.693

1.066

0.863

—

0.867

—

(17.67)

ROIC%

—

(21.01)

(32.63)

(29.55)

(17.67)

(1.40)

(25.28)

—

(11.82)

Return on equity%

—

(14.73)

(18.16)

(18.09)

(11.82)

(1.31)

(16.41)

—

(9.62)

Return on assets%

—

(12.49)

(12.88)

(17.73)

(9.62)

(1.21)

(12.69)

—

(1.16)

EPSNT$

—

(1.21)

(1.82)

(1.75)

(1.16)

(0.14)

—

33.58

EPS growth%

—

(50.22)

3.77

33.58

87.56

3.77

—

11.14

Bookvalue per shNT$

—

8.21

12.56

8.80

11.14

10.99

10.70%

—

(1.00)

FCF per shareNT$

—

(1.05)

(1.26)

(1.86)

(1.00)

(0.14)

—

Dividend per shNT$

—

Div yield (avg)%

—

Payout ratio%

—

61.27

Shares (diluted)M

—

34.04

37.51

44.77

46.31

◌46.31

10.80%

—

(3.43)

Buyback yield%

—

(10.19)

(19.35)

(3.43)

◌—

(10.19)

—

0.033

D/E ratiox

—

0.112

0.058

0.056

0.033

0.057

—

1.780

Enterprise valueNT$B

—

1.002

0.865

0.977

1.343

(1.29%)

—

LT debtNT$M

—

Peers (US$40.15M)

Cap (US$)

Greenyn Biotechnology…

39.95M

—

Anti-Microbial Savior…

38.89M

—

Advagene Biopharma Co.…

37.48M

—

Oncoinvent ASA

40.58M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(279.1)

(215.2)

Own earn%

—

Sh yield%

(3.43)

(10.19)

Owners

Insiders/Inst%

5.99

18.20

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/4

Revenue growth years

1/3

EPS growth years

2/3

Dividend streakyrs

Op margin range%

−44143–−1363

$1 testx

—

Incr. ROIC%

−11

Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies.

Growth vs revenue

Latest

Trend

3Y CAGR

Rel growth

Revenue

NT$5.548M

47.95%

1.00×

Cost of revenue

NT$3.748M

71.20%

1.55×

Operating expenses

NT$77.44M

17.51%

0.50×

Asset mix

Trend

Other

90.38%

Cash and investments

9.62%

Reinvestment returns

No breakdown available